Topline data from a Phase 2b trial showed that the investigative therapy acebilustat taken once daily can reduce the number and frequency of pulmonary exacerbations in patients with cystic fibrosis.

Pulmonary exacerbations — temporary worsening of lung function — are caused by uncontrolled lung inflammation, and these acute episodes can lead to the chronic decline of lung function and a shortened lifespan.

Acebilustat is an inhibitor of an enzyme involved in the production of leukotriene B4 (LTB4), a potent signaling molecule that promotes inflammation. The investigational therapy was developed by Celtaxsys to reduce inflammationthat contributes to the development and worsening of diseases such as CF.